A phase 1 study, presented at the 2017 American Society of Clinical Oncology Annual Meeting, found that including daratumumab can improve patient response to treatment in newly diagnosed multiple myeloma.
A combination of proteasome inhibitors and immunomodulatory drugs in the standard of care has improved outcomes in patients with multiple myeloma over the past 10 years. However, these patients can relapse even after complete remission in first-line indications. A phase 1 study, presented at the 2017 American Society of Clinical Oncology Annual Meeting, found that including daratumumab, an antibody that binds and inhibits the CD38 receptor, can improve patient response to treatment.
The trial enrolled newly diagnosed patients, regardless of transplantation eligibility. Patients were administered daratumumab at 16 mg/kg weekly for cycles 1 and 2, every other week for cycles 3 to 6, and once in 4 weeks thereafter. Carfilzomib (K) was administered on days 1, 8, and 15 of each 28-day cycle (20 mg/m2 on day 1 of cycle 1, and 36 mg/m2 or 70 mg/m2 based on tolerability of first dose) for most of the 13 cycles or elective discontinuation for allogenic stem cell transplant. The treatment also included 25 mg lenalidomide (Revlimid, R) given on days 1 to 21 and dexamethasone (d), 20 to 40 mg weekly.
The primary endpoint for this very early phase trial was tolerability.
Twenty-two patients received a median of 8 (range = 1-10) treatment cycles, with a median duration of follow-up 7.4 months (range = 4.0-9.3). Six patients (27%) discontinued treatment, with serious adverse events observed in 46% of patients, 14% of which were possibly related to daratumumab.
Eighteen patients (82%) experienced a grade 3/4 treatment-emergent adverse event (TEAE). The most common grade 3/4 TEAEs (more than 10%) were lymphopenia (50%) and neutropenia (23%). No grade 5 TEAE was reported. All daratumumab-associated infusion reactions were less than grade 2.
The authors concluded that the addition of daratumumab to KRd was well tolerated, consistent with that previously reported for KRd, with no additional toxicity observed with the addition of daratumumab. No grade 3/4 toxicities were noted. The treatment was highly effective with 100% overall response rate, as well as a 100% 6-month progression-free survival. The depth of response improved with treatment duration. They claimed that daratumumab can be a feasible option for induction therapy in newly diagnosed patients with multiple myeloma.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More